Rejuvenate Biomed

  • Home
  • Our team
  • News
  • Events
  • Contact
  • Home
  • Our team
  • News
  • Events
  • Contact
Home News

News

Clinical Phase 2b strategy endorsed by Advisory Board

Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia. After a fruitful brainstorming session, the Advisory Board supported the Phase 2b trial design, which will be initiated in 2023.

LEARN MORE

Groundbreaking clinical trial started

Rejuvenate Biomed started clinical trial with RJx-01 for treating sarcopenia. This trial marks Rejuvenate’s maturation from preclinical to clinical stage and is accompanied by the growth of the team and a move to the new Health Campus in Diepenbeek.

LEARN MORE

€15.7 million Series B round secured

Through this investment, Rejuvenate Biomed becomes a clinical-stage company. The funding was led by Rejuveron Life Sciences and Vesalius Biocapital.

LEARN MORE

Preclinical data reviewed by Scientific Advisory Board

The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders.

LEARN MORE

Dr. Ajit Shetty appointed as Chair of the Board

Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections.

LEARN MORE
  • 1
  • 2
  • 3
  • 4

Rejuvenate Biomed

Rejuvenate Biomed is a science based healthy aging company developing prescription drugs to promote healthy aging.

LETS TALK

Wetenschapspark 13
3590 Diepenbeek
Belgium

View map

Agoralaan Abis
3590 Diepenbeek
Belgium

View map

info@rejuvenatebiomed.com

© Copyright 2017-2021 Rejuvenate Biomed NV. All Right Reserved.
  • Privacy Policy
  • Cookie Policy

This website uses cookies to enhance your browsing experience. More information.